GSK Augmentin ES Needs "Boundary" On Resistant Strains Covered, FDA Cmte
Executive Summary
GlaxoSmithKline should indicate an upper "boundary" of penicillin resistance that its antibiotic Augmentin ES is expected to effectively treat, FDA's Anti-Infective Drugs Advisory Committee suggested Jan. 30.